Trulicity patent expiration 2027?

There isn’t a single “Trulicity patent expiration” date. Trulicity (dulaglutide) is protected by multiple patents plus regulatory exclusivities, and expiration depends on the country and the type of protection.

Key points to consider:
- Regulatory exclusivity for biologics (US): In the United States, the 12-year data exclusivity for biologics runs from first approval (2014–2015 era for dulaglutide) and effectively blocks relying on originator data until around 2026. That can delay generic/biosimilar entry even if patents expire earlier.
- Patent protections: There are multiple patents (composition of matter, formulation, methods of use, manufacturing, etc.). Some may expire in the mid-to-late 2020s or later, and patent term extensions or adjustments can push protection further.
- Other regions: The European Union and other jurisdictions have their own data/market exclusivities (often around 10 years in the EU, with possible pediatric extensions), plus national patents. Dates vary.

So, 2027 could be a plausible window for potential biosimilar entry in some places, but it’s not guaranteed and depends on the specific patents and legal outcomes in each region.

If you tell me the country or region you care about, I can summarize the current patent and exclusivity status for that area and point to sources (e.g., USPTO, Google Patents, Espacenet, FDA Purple Book, EU Patent Register).